Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Assets (2020 - 2025)

Historic Assets for TScan Therapeutics (TCRX) over the last 6 years, with Q3 2025 value amounting to $262.2 million.

  • TScan Therapeutics' Assets fell 2465.38% to $262.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $262.2 million, marking a year-over-year decrease of 2465.38%. This contributed to the annual value of $371.1 million for FY2024, which is 3636.57% up from last year.
  • TScan Therapeutics' Assets amounted to $262.2 million in Q3 2025, which was down 2465.38% from $298.6 million recorded in Q2 2025.
  • Over the past 5 years, TScan Therapeutics' Assets peaked at $374.9 million during Q2 2024, and registered a low of $130.0 million during Q2 2021.
  • Its 5-year average for Assets is $249.5 million, with a median of $251.5 million in 2024.
  • Its Assets has fluctuated over the past 5 years, first soared by 27819.57% in 2021, then plummeted by 2465.38% in 2025.
  • TScan Therapeutics' Assets (Quarter) stood at $188.1 million in 2021, then grew by 5.84% to $199.1 million in 2022, then soared by 36.7% to $272.1 million in 2023, then surged by 36.37% to $371.1 million in 2024, then dropped by 29.34% to $262.2 million in 2025.
  • Its last three reported values are $262.2 million in Q3 2025, $298.6 million for Q2 2025, and $332.7 million during Q1 2025.